Researchers Identify POLG Enzyme as Key to Breast Cancer
A newly identified link between mitochondrial function and cell spread could offer a path for treating aggressive breast cancer.
Updated on Oct. 31, 2026 in Cancer
Scientists have determined that the POLG enzyme acts as a promoter for triple-negative breast cancer (TNBC) metastasis. This finding reveals how cancer cells increase their energy production to facilitate the spread of the disease.
Why it matters
Understanding the metabolic mechanisms behind TNBC metastasis is crucial for developing targeted therapies. This discovery highlights how cancer-associated fibroblasts drive metabolic reprogramming to support tumor progression.
Researchers found that POLG increases the functionality of oxidative phosphorylation complexes, enabling TNBC cells to utilize both internal and external mtDNA for ATP production.
The players
Cell Death & Disease
This peer-reviewed medical journal publishes research covering the molecular mechanisms of cell death and disease development.
The details
The study demonstrates that cancer-associated fibroblasts stimulate TNBC cells to increase POLG expression, which is transactivated by the cooperation of ERRα and PGC-1α. Experiments showed that inhibiting POLG activity significantly reduced the metastatic potential of these cancer cells in both in vitro and in vivo models.
Timeline
October 31, 2026: Research findings were published in the journal Cell Death & Disease.
The Big Picture
This research updates the understanding of metabolic pathways within the ongoing study of metabolic reprogramming in oncology. It confirms that mitochondrial enzyme modulation serves as a critical bridge between cell signaling and tumor spread.
While these findings are currently confined to laboratory research, they identify a specific target for future drug development in aggressive breast cancer treatments. Patients should consult their oncologists regarding the current standard of care for TNBC.
The takeaway
Targeting mitochondrial DNA replication enzymes offers a promising new avenue for stopping the spread of triple-negative breast cancer. Future clinical research will focus on developing pharmacological inhibitors that can safely block POLG activity in human patients.
Further reading
For more information on current treatment landscapes, visit the Cancer section.
More information
View the peer-reviewed research article to read the full study.
